Navigation Links
QIAGEN Announces Third Co-Development Program for Companion Diagnostics Paired With Lilly's Investigational Cancer Compounds
Date:11/18/2013

HILDEN, Germany, and GERMANTOWN, Maryland, November 18, 2013 /PRNewswire/ --


  • Collaboration aims to use QIAGEN's companion diagnostic development capabilities to create a companion diagnostic paired with a novel oncology compound from Lilly
  • New partnership builds on Lilly-QIAGEN framework agreement for development of advanced diagnostic tests to guide treatment with innovative therapies
  • Third project follows success of FDA-approved therascreen  KRAS test in metastatic colorectal cancer and clinical development of JAK2 genetic test in blood cancers

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced an agreement with Eli Lilly and Company (NYSE: LLY) to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic information in patient samples to enable personalized decisions on treatments. The latest collaboration, involving an undisclosed Lilly compound and an undisclosed molecular diagnostic target, builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed earlier this year.

QIAGEN and Lilly are long-standing partners in personalized healthcare. QIAGEN's therascreen® KRAS RGQ PCR Kit has been widely adopted by laboratories since its July 2012 approval by the Food and Drug Administration (FDA) as a companion diagnostic. The therascreen KRAS Test detects gene mutations in metastatic colorectal
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
2. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
3. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
4. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
5. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
6. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
7. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
8. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
9. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
10. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
11. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier this ... L. Sherley, director of the Adult Stem Cell Technology Center, ... and under appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the essence ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... the Sale of Ready to Drink,Suite of Nutritional Supplements to Provider ... ... BASKING RIDGE, N.J., June 5 Millennium Biotechnologies,Inc., wholly owned subsidiary ... it has entered into an,amendment of it,s November 9th 2007 Master ...
... Compendia Bioscience today,announced that it has signed ... GSK ) for Oncomine(TM) Enterprise Edition, a,value-added ... Edition builds upon the features of Oncomine,Professional ... to securely,view proprietary gene expression data in ...
... LAWRENCE, Mass., June 5 NxStage Medical, Inc.,(Nasdaq: ... announced that Jeffrey H. Burbank, Chief Executive Officer, and,Robert ... the William,Blair 28th Annual Growth Stock Conference on June ... NxStage,s investor presentation is scheduled for Wednesday, June ...
Cached Biology Technology:Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 2Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 3GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience 2NxStage Medical to Present at William Blair Growth Stock Conference 2
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... multiple sclerosis (MS), neuroradiologists and neurologists of the University ... visualize inflammatory tissue damage, most of which had remained ... new contrast medium, Gadofluorine M, in magnetic resonance imaging. ... edition of the renowned medical journal Brain . ...
... About 4,000 children in the United States die every ... septic shock, and researchers are pushing the boundaries of ... the condition. But a simple measure of an immune ... the hospital for septic shock can predict survival in ...
... a pilot study in children with sarcoma, researchers at ... could prove beneficial in treating high-risk forms of this ... vaccine as well as a standard flu vaccine to ... findings, published in the August 1 issue of ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
Request Info...
Request Info...
Biology Products: